Share Prices & Company Research

Stockbroking

Astrazeneca Plc

Current Price 10625.00p Bid 10586.00p Ask 10630.00p Change 2.54%
Last Updated: 10/07/2025 17:14. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2024

Revenue
£54,073.00m
Operating Profit/Loss
£10,003.00m
Dividend yield (%)
2.20
Total dividend for year
$n/a
Dividend cover
2.65
P/E Ratio
17.30
More Financials

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Dr Aradhana Sarin
CFO & Executive Director
Dr Euan Ashley
Non-Executive Director
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Rene Haas
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Ms Anna Manz
Non-Executive Director
Ms Birgit Conix
Non-Executive Director
Ms Diana Layfield
Non-Executive Director
Ms Karen Knudsen
Non-Executive Director

Stock Details

EPIC
AZNL
ISIN
GB0009895292
Shares in Issue
1,264.16m
Market cap
£134,317.29m

Analyst Views (3)

Strong Buy
 
0%
Buy
 
66.67%
Hold
 
33.33%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
10,625.00p
Bid Price
10,586.00p
Ask Price
10,630.00p
Volume
424,594
Change Today
263.00p
% Change Today
2.54%
Open
10,473.00p
Previous Close
10,625.00p
Intraday High
10,678.00p
Intraday Low
10,473.00p
52 Week High
13,250.00p
52 Week Low
9,642.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

Berenberg raises target price on AstraZeneca 09/07/2025 09:01:41 Sunday newspaper round-up: Trade, AstraZeneca, Tax hikes 06/07/2025 12:41:08 London close: FTSE finishes flat ahead of Trump tariff deadline 04/07/2025 17:48:59 AstraZeneca's Imfinzi gets EU green light 04/07/2025 07:10:04 AstraZeneca's Datroway gets green light from FDA 24/06/2025 07:10:10 AstraZeneca launches strategic research collaboration with China's CSPC Pharmaceuticals 13/06/2025 09:51:12 AstraZeneca's Calquence receives European Commission approval 06/06/2025 08:05:26 EU recommends AstraZeneca bladder cancer treatment for approval 27/05/2025 08:36:21 London close: Stocks finish choppy week in the black 16/05/2025 16:32:35 Pharma stocks slide as Trump threatens price cuts in US 12/05/2025 10:13:59 Sunday newspaper round-up: US-China, Aerospace, Pharma 11/05/2025 14:38:17 London close: FTSE snaps 16-day win streak ahead of Fed 07/05/2025 15:05:52 GSK, AstraZeneca slide after FDA unveils new vaccine lead 07/05/2025 11:32:30 AstraZeneca receives 'positive high-level results' results from Enhertu trial 07/05/2025 09:23:02 AstraZeneca's Calquence gets Europe approval for MCL 06/05/2025 08:02:15 AstraZeneca's Breztri meets all primary endpoints in asthma trials 02/05/2025 10:00:41 AstraZeneca discontinues prostate cancer treatment trial 29/04/2025 07:10:43 AstraZeneca receives positive Phase III trial results from Enhertu study 22/04/2025 08:05:27 AstraZeneca's Enhertu gets further EU approval 04/04/2025 07:02:52 UK pharma stocks avoid selloff 03/04/2025 10:18:17 AstraZeneca makes regulatory progress with Imfinzi, Calquence 31/03/2025 07:21:11 AstraZeneca spending $2.5bn on new R&D centre, biotech deals in China 21/03/2025 11:17:16 AstraZeneca buys biotech firm Esobiotec for up to $1bn 17/03/2025 07:21:46 AstraZeneca hails trial results for imfinzi on gastric cancer 07/03/2025 07:03:43 AstraZeneca's Imfinzi gets recommended for fresh EU approval 03/03/2025 07:26:27

Income Statement

Year End Date
31 Dec 2024
31 Dec 2023
 
$ (M)
$ (M)
Continuing Operations
Revenue
54,073.00
45,811.00
Operating Profit/Loss
10,003.00
8,193.00
Net Interest
-1,284.00
-1,282.00
Pre-Tax Profit
8,691.00
6,899.00
Profit After Tax from continuing operations
7,041.00
5,961.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
7,041.00
5,961.00
Attributable to:
Equity Holders of Parent Company
7,035.00
5,955.00
Minority Interests
6.00
6.00
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2024
31 Dec 2023
Basic
454.00c
384.00c
Diluted
450.00c
381.00c
Adjusted
821.00c
726.00c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
11,647.00
10,502.00
Intangible Assets
58,202.00
58,137.00
Investment Properties
n/a
n/a
Investments
1,900.00
1,677.00
Other Financial Assets
182.00
228.00
Other Non-Current Assets
6,277.00
5,521.00
Current Assets
Inventories
5,288.00
5,424.00
Trade & Other Receivables
12,972.00
12,126.00
Cash at Bank & In Hand
5,488.00
5,840.00
Current Asset Investments
n/a
n/a
Other Current Assets
2,079.00
1,664.00
Other Assets
n/a
n/a
Total Assets
104,035.00
101,119.00

Liabilities

Year End Date
31 Dec 2024
31 Dec 2023
 
$ (M)
$ (M)
Current Liabilities
Borrowings
2,676.00
5,400.00
Other Current Liabilities
25,190.00
25,142.00
Total Current Liabilities
27,866.00
30,542.00
Non-Current Liabilities
Borrowings
27,619.00
23,222.00
Provisions
4,226.00
2,844.00
Other Non-Current Liabilities
3,453.00
5,345.00
Total Non-Current Liabilities
35,298.00
31,411.00
Other Liabilities
n/a
n/a
Total Liabilities
63,164.00
61,953.00

Net Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
$ (M)
$ (M)
Net Assets
40,871.00
39,166.00

Capital & Reserves

Year End Date
31 Dec 2024
31 Dec 2023
 
$ (M)
$ (M)
Share Capital
388.00
388.00
Share Premium Account
35,226.00
35,188.00
Other Reserves
2,012.00
2,065.00
Retained Earnings
3,160.00
1,502.00
Shareholders Funds
40,786.00
39,143.00
Minority Interests/Other Equity
85.00
23.00
Total Equity
40,871.00
39,166.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
2nd Interim
20 Feb 2025
24 Mar 2025
210.00¢
1st Interim
08 Aug 2024
09 Sep 2024
100.00¢
2nd Interim
22 Feb 2024
25 Mar 2024
197.00¢
1st Interim
10 Aug 2023
11 Sep 2023
93.00¢
2nd Interim
23 Feb 2023
27 Mar 2023
197.00¢
1st Interim
11 Aug 2022
12 Sep 2022
93.00¢
2nd Interim
24 Feb 2022
28 Mar 2022
197.00¢
1st Interim
12 Aug 2021
13 Sep 2021
90.00¢
2nd Interim
25 Feb 2021
29 Mar 2021
190.00¢
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2024
31 Dec 2023
Dividend growth
6.90%
n/a%
Dividend yield
2.20%
2.00%
Dividend cover
2.65
2.50


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.